Manager Project

GRAHAM K. BILTER

925-***-**** (cell)

925-***-**** (home)

*******@*****.***

Biotechnology Professional Project- and Customer-Focused Enabling Innovation, Efficiency and Safety

Skills:

• Research and process development for small-molecule drugs and biologics

• Cell-based and in vitro assays: optimization, validation, scale-up, high-throughput screening

• Antibodies: Western blotting, ELISA, MSD/ECL assays, labeling, immunoprecipitation

• Designing protocols and writing SOPs suitable for GLP compliance

• Excel, Word, and PowerPoint, Excel Visual Basic, SoftMax Pro GxP; LIMS

• Processing and QC for large amounts of data in support of Bioinformatics and IT infrastructure

• Planning, executing and supervising highly complex and variable processing workflows

• Sourcing, organization, cost breakdown, and tracking of consumables

• Automated liquid handling: operation, programming, troubleshooting, calibration, maintenance

• Mammalian cell culture: primary, immortalized; adherent, suspension; continuous perfusion bioreactors

• Cell plating, cryopreservation, banking, transfection, stable clone generation ; BSL2 lab work

• Drug compound library management: preparation, dilution, customized plate formatting

• Gel electrophoresis: proteins, DNA and/or RNA

• PCR and RT-PCR, gene cloning, primer design, site-directed mutagenesis, RNA interference

• Protein expression: baculoviral, bacterial and eukaryotic systems

• Protein purification: native proteins, His- and GST-fusions, large-scale fractionation and ultrafiltration

• Collaborating with co-workers, vendors and clients from diverse backgrounds to move projects forward

• Producing and presenting quality results within tight deadlines and budget constraints

• Adapting to abrupt changes in project and customer priorities; open to learning new skills

Experience:

Contractor, MedImmune LLC, Hayward and Mountain View, CA. November 2013 – Present.

• PK-PD; pre-clinical and clinical assay development. GLP-compliant bioanalysis for pharmacokinetics,

immunogenicity and biomarkers.

R&D Scientist, Odyssey Thera, Inc., San Ramon, CA. November 2002 – May 2013.

• Manager for automated liquid handling and compound preparation labs

• Developed cell-based assays in 384-well plates: Protein fragment Complementation Assays (PCAs),

cytotoxicity, proliferation, luciferase reporter, ATP, BCA, ROS, and mitochondrial activity

• Executed liquid handling workflow for high-throughput screening projects: up to 120 plates per day, with

multiple drug panels, reference compounds and treatment times

• Designed protocols, wrote SOPs, and created versatile Excel-based tools for experimental design, data

processing, sample tracking, plate formatting, and workflow management

• Performed cell culture, transfection, plating, banking and creation of stable clones

• Processed large sets of raw data and presented results at meetings

• Supervised research associates and intern in molecular biology, compound preparation and automated

liquid handling labs

(Sr.) Research Associate – Associate Scientist, Celgene Corp. (Signal Research Division), San Diego, CA.

November 1994 – October 2002.

• Assessed the effects of small-molecule drugs on signal transduction pathways in various cell lines and

tumor tissues using soft agar cultures, focus formation assays, flow cytometry, transient transfections, and

Western blots

• Developed in vitro assays and performed high-throughput screening of small-molecule drugs

• Performed research for virology (HPV, HCV, HIV) and cancer; published in peer-reviewed journals

• Manager for automated DNA sequencers

• Maintained stocks of antibodies, restriction enzymes and other reagents for general use

• Received full funding for Professional Certificate courses at UC San Diego

Graduate Student, Ph.D. program in Biology, University of California, San Diego, La Jolla, CA. September

1993 – July 1994.

Five rotation projects, each lasting seven weeks. Topics included:

• Vaccine development for cytomegalovirus

• T cell selection in fetal mice

• Amplification of T cell clones from splenocytes

• Molecular evolution and allelic polymorphism in human and Drosophila genes

• Regulation of immunoglobulin kappa light chain gene expression

Research Assistant, Process Cell Biology and Clinical Production groups, Bayer AG, Berkeley, CA. July 1991 –

July 1993.

• Studied cell growth and antibody production in hybridomas and myelomas; optimized medium

formulations and performed immunoassays

• Refined a protocol for using the Elzone® machine as a cell-counting device

• Monitored and maintained continuous perfusion cultures in 20- and 200-liter bioreactors

• Received full funding for UC Berkeley Extension courses in immunology and physical chemistry

Plasma Filtration Worker, Bayer AG, Berkeley, CA. December 1989 – June 1991.

• Assisted in large-scale processing of human blood plasma products for clinical use: Alpha-1 Proteinase

Inhibitor, Factor VIII, and Antithrombin-III

Education:

B.A. in Biology, University of California, Davis; with high honors. GPA: 3.76. Elected to Phi Beta Kappa honor

society.

Professional Certificate in Drug Discovery and Development, University of California, San Diego. 255 hours of

instruction. GPA: 3.88.

Publications:

MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T,

Michnick SW, Westwick JK. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat

Chem Biol. 2006 Jun; 2(6):329-37. Epub 2006 May 7.

Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, Brenner DA. JNK mediates hepatic ischemia

reperfusion injury. J Hepatol. 2005 Jun; 42(6):850-9. Epub 2005 Apr 7.

Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M, Bilter GK, Stein B. Inhibition of tumor

growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J

PharmacolExpTher. 2005 Apr; 313(1):325-32. Epub 2004 Dec 30.

Yu H, West M, Keon BH, Bilter GK, Owens S, Lamerdin J, Westwick JK. Measuring drug action in the cellular

context using protein-fragment complementation assays. Assay Drug Dev Technol. 2003 Dec; 1(6):811-22.

Pruitt K, Pruitt WM, Bilter GK, Westwick JK, Der CJ. Raf-independent deregulation of p38 and JNK mitogen-

activated protein kinases are critical for Ras transformation. J Biol Chem. 2002 Aug 30; 277(35):31808-17. Epub

2002 Jun 24.

García-Martínez LF, Bilter GK, Wu J, O'Neill J, Barbosa MS, Kovelman R. In vitro high-throughput screening

assay for modulators of transcription. Anal Biochem. 2002 Feb 1; 301(1):103-10.

Kovelman R, Bilter GK, Roman A, Brown DR, Barbosa MS. Human papillomavirus type 6: classification of

clinical isolates and functional analysis of E2 proteins. J Gen Virol. 1999 Sep; 80 (Pt 9):2445-51.

Kovelman R, Bilter GK, Glezer E, Tsou AY, Barbosa MS. Enhanced transcriptional activation by E2 proteins

from the oncogenic human papillomaviruses. J Virol. 1996 Nov; 70(11):7549-60.

Abstracts:

KA Smith, JK Westwick, M Boluro-Ajayi, G Bilter, D Zhu, B Bennett, Y Satoh, B Stein, M Shirley, and BW

Ennis. Inhibition of tumor growth, angiogenesis and tumor cell proliferation by a small molecule inhibitor of c-

Jun N-terminal kinase (JNK).Proceedings American Association for Cancer Research, 43: 1079, 2002.

BW Ennis, KA Smith, JK Westwick, M Boluro-Ajayi, G Bilter, B Bennett, Y Satoh, and B Stein. Inhibition of c-

Jun N-terminal kinase (JNK) blocks tumor growth: effects on angiogenesis and tumor cell proliferation.

Proceedings AACR-NC-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 7:

3772s, 2001.

U.S. Patent:

Barbosa MS, Kovelman R, and Bilter, G. Dual reporter system and methods of use therefor. Patent #6,603,578.

May 16, 2000.

Contact this candidate